Research To Practice | Oncology Videos

Latest Episodes:

Non-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual Meeting Jul 09, 2025

Show notes

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Christopher Flowers, Dr Ann LaCasce and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics:

Introduction (0:00)
Selection and Sequencing of Available Therapies for Diffuse Large B-Cell Lymphoma — Dr Flowers (2:24)
Evolving Management Paradigm for Mantle Cell Lymphoma — Dr Phillips (31:53)
Integration of Novel Therapies into the Management of Follicular Lymphoma — Dr LaCasce (54:51)
Integrating Bispecific Antibodies into the Management of Non-Hodgkin Lymphoma (NHL) — Dr Brody (1:11:22)
Current Role of CAR T-Cell Therapy in Various NHL Subtypes — Dr Abramson (1:37:55)

CME information and select publications

For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress Jul 07, 2025

Show notes

Featuring perspectives from Dr Anne Chiang, Ms Elizabeth Krueger, Ms Beth Sandy and Dr Erin Schenk, including the following topics:

Introduction: Overview of Bispecific Antibodies (0:00)
Biology of Small-Cell Lung Cancer (SCLC) and Review of Its Initial Management (13:37)
Case: 63-year-old man — Ms Krueger (23:36)
Current Role of Tarlatamab in Therapy for SCLC (33:40)
Case: 70-year-old woman — Ms Sandy (43:41)
Future Directions in the Management of SCLC (50:45)
Case: 81-year-old man — Ms Krueger (1:01:24)
Unique Considerations in SCLC Management (1:09:29)
Case: 67-year-old woman — Ms Sandy (1:22:53)

NCPD information and select publications

For Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS Congress Jul 05, 2025

Show notes

Featuring perspectives from Dr Christopher Flowers, Dr Manali Kamdar, Ms Robin Klebig and Ms Caitlin Murphy, including the following topics:

Introduction: Overview of Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma (0:00)
Current and Future Use of Bruton Tyrosine Kinase Inhibitors for Mantle Cell Lymphoma (16:09)
First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) (40:03)
Role of Loncastuximab Tesirine for Patients with Relapsed/Refractory (R/R) DLBCL (57:31)
Role of Tafasitamab for Patients with R/R DLBCL and Follicular Lymphoma (1:16:59)

NCPD information and select publications

Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting Jul 03, 2025

Show notes

Featuring perspectives from Dr Harold J Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Hope S Rugo and Dr Joyce O'Shaughnessy, moderated by Dr Rugo, including the following topics:

Introduction (0:00)
Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Cortés (3:52)
Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC — Dr Kalinsky (23:10)
Available Therapies for Patients with HR-Positive, HER2-Negative Disease Progressing on CDK4/6 Inhibition — Dr Burstein (48:09)
Current and Potential Future Role of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr O'Shaughnessy (1:04:00)
Current and Future Strategies for Patients with Endocrine-Refractory HR-Positive mBC — Dr Rugo (1:22:28)
Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Prof Dent (1:42:51)

CME information and select publications

Colorectal Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting Jul 02, 2025

Show notes

Featuring perspectives from Dr Andrea Cercek, Dr Arvind Dasari, Dr J Randolph Hecht, Dr Pashtoon Kasi and Prof Eric Van Cutsem, moderated by Dr Hecht, including the following topics:

Introduction (0:00)
Role of Circulating Tumor DNA (ctDNA) Evaluation in Nonmetastatic Colorectal Cancer (CRC) — Dr Dasari (2:20)
Role of Immune Checkpoint Inhibitors in the Management of Nonmetastatic Microsatellite Instability-High (MSI-H) CRC — Dr Cercek (28:32)
Management of Oligometastatic Disease and Hepatic-Only Metastases in CRC; Role of ctDNA Evaluation in Metastatic Disease — Dr Kasi (54:07)
Role of Immune Checkpoint Inhibitors in the Management of MSI-H Metastatic CRC (mCRC) — Dr Hecht (1:14:34)
Identification and Care of Patients with mCRC and Actionable Genomic Alterations — Prof Van Cutsem (1:38:17)

CME information and select publications

Ovarian and Endometrial Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting Jun 30, 2025

Show notes

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley, Dr Ritu Salani, Dr Alessandro D Santin and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

Introduction (0:00)
Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Liu (2:00)
Current Management of Relapsed/Refractory (R/R) OC; Promising Novel Agents and Strategies Under Investigation — Dr O'Malley (27:23)
Role of HER2-Targeted Therapy in Advanced OC, Endometrial Cancer (EC) and Other Gynecologic Cancers — Dr Santin (50:22)
First-Line Therapy for Advanced EC — Dr Westin (1:15:00)
Current Therapeutic Options for R/R EC; Novel Investigational Strategies for Newly Diagnosed and Recurrent Disease — Dr Salani (1:36:45)

CME information and select publications

For Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS Congress Jun 27, 2025

Show notes

Featuring perspectives from Ms Ilene Galinsky, Dr Michael J Mauro, Dr Neil P Shah and Dr Sara M Tinsley-Vance, including the following topics:

Introduction: Chronic Myeloid Leukemia (CML) as a Model for Targeted Treatment (0:00)
Biology of CML; Role of First- and Second-Generation Tyrosine Kinase Inhibitors (TKIs) as Initial Treatment for Chronic-Phase (CP) CML (12:37)
Role of Asciminib for Newly Diagnosed CP-CML (47:46)
Feasibility of TKI Discontinuation for Patients with Sustained Response to Treatment (1:14:06)
Management of CP-CML After Failure of Initial Therapy (1:23:04)

NCPD information and select publications

Prostate Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting Jun 25, 2025

Show notes

Featuring perspectives from Dr Neeraj Agarwal, Dr Andrew J Armstrong, Dr Himisha Beltran, Dr Rana R McKay and Dr Fred Saad, moderated by Dr McKay, including the following topics:

Introduction (0:00)
Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Saad (2:12)
Current Treatment for Metastatic HSPC — Dr Armstrong (26:12)
Role of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Agarwal (49:31)
Current and Future Use of Radiopharmaceuticals for mCRPC — Dr McKay (1:12:51)
Promising Novel Agents and Strategies Under Investigation for the Management of Prostate Cancer — Dr Beltran (1:36:11)

CME information and select publications

IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies Jun 24, 2025

Show notes

Featuring an interview with Dr Patrick Y Wen, including the following topics:

Glioma classification (0:00)
Efficacy and safety of vorasidenib in the management of IDH-mutant gliomas (4:50)
Case: A woman in her early 30s with a Grade 2 astrocytoma and an IDH R132H mutation and residual disease postoperatively (11:55)
Case: A man in his early 40s experiencing stable disease with vorasidenib after subtotal resection (21:46)
Ongoing trial investigating vorasidenib in IDH-mutant gliomas (27:30)
Current and emergent strategies for the management of glioblastoma (31:27)
Optimizing patient care and quality of life (46:24)

CME information and select publications

IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies (Companion Faculty Lecture) Jun 23, 2025

Show notes

Featuring a slide presentation and related discussion from Dr Patrick Y Wen, including the following topics:

Classification and pathologic diagnosis of gliomas (0:00)
Role of IDH inhibitors in the management of low-grade gliomas (6:37)
Ongoing trials and remaining questions in the management of IDH-mutant gliomas (19:53)

CME information and select publications